Kissei Pharmaceutical Co (JP:4547) has released an update.
Kissei Pharmaceutical Co. has announced the first commercial sale in Germany of YSELTY, a new treatment for uterine fibroids developed and licensed out to Theramex. YSELTY is a GnRH receptor antagonist that has been approved in Europe for use with or without Add-back therapy, offering an alternative for patients unable to take hormonal agents. The financial impact of this launch has been factored into Kissei’s consolidated earnings forecast for the fiscal year ending March 2025.
For further insights into JP:4547 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com